Linfoma de Hodgkin na infância e adolescência: 15 anos de experiência com o protocolo DH-II-90

Abstract

Bras. Hematol. Hemoter. 2010;32(4):295-302.

A Terapêutica Cirúrgica e o Protocolo DH-II-90 no Tratamento da Doença de Hodgkin em Jovens e Adultos: um Estudo Ecológico

“…Logo, a fim de reduzir a prática de estadiamento cirúrgico, foram desenvolvidos métodos como a terapêutica do protocolo DH-II-90, o qual consiste na terapia combinada de quimioterapia e radioterapia 23 . O abandono da prática mais invasiva tornou, hoje, maior a sobrevida global desses pacientes, uma vez que a taxa de cura da abordagem moderna é de aproximadamente 85% dos casos 14,15,24 .…”

“…O abandono da prática mais invasiva tornou, hoje, maior a sobrevida global desses pacientes, uma vez que a taxa de cura da abordagem moderna é de aproximadamente 85% dos casos 14,15,24 . Ademais, a terapêutica combinada permite reduzir os índices de toxicidade de ambas as terapias quando isoladas, e o tratamento da patologia disseminada pela quimioterapia assim como pela radioterapia realiza o controle localizado do tumor ao inibir o aumento das células tumorais 6,23 .…”

3′ untranslated region A>C (rs3212227) polymorphism of Interleukin 12B gene as a potential risk factor for Hodgkin’s lymphoma in Brazilian children and adolescents

“…Hodgkin's lymphoma (HL) is a neoplasm that reaches the lymph nodes and lymphatic system and generally has a good prognosis in the pediatric population. [1][2][3] It is characterized by the large number of neoplastic cells called Hodgkin or Reed-Sternberg (HRS), and by infiltration of different types of immune system cells into the tumor microenvironment, including T and B cells. [4][5][6] Based on histological differences and cellular composition, classical Hodgkin lymphoma (CHL) is subdivided into four subtypes: nodular sclerosis classical Hodgkin lymphoma (NSCHL), mixed cellularity classical Hodgkin lymphoma (MCCHL), lymphocyte depletion classical Hodgkin lymphoma (LDCHL), and lymphocyterich classical Hodgkin lymphoma (LRCHL).…”

“…[4][5][6] Based on histological differences and cellular composition, classical Hodgkin lymphoma (CHL) is subdivided into four subtypes: nodular sclerosis classical Hodgkin lymphoma (NSCHL), mixed cellularity classical Hodgkin lymphoma (MCCHL), lymphocyte depletion classical Hodgkin lymphoma (LDCHL), and lymphocyterich classical Hodgkin lymphoma (LRCHL). 2,[4][5][6][7][8] The clinical and pathological features of CHL result from an immune dysfunction characterized by deregulation of the expression of various cytokines and chemokines and an inadequate immune response due to the poor immunogenicity of HRS cells. 9,10 Among these cytokines are interferons (IFNs), which present a wide range of immunomodulatory activities, including the activation of natural killer (NK) cells, cytotoxic T cells, and the promotion of T helper 1 (Th1) type response.…”